Filings & corporate actions
- 29 OctresultsResults · Q2 FY27 · standalone+1.3%NSE
- 14 OctshareholdingShareholding · 30 Sept 2026+0.3%NSE
- 1 SeptdividendDividend · ₹5.00 per share+2.7%
- 30 JulresultsResults · Q1 FY27 · standalone+5.9%NSE
- 13 JulshareholdingShareholding · 30 Jun 20260.0%NSE
- 14 MayresultsResults · Q4 FY26 · standalone-1.8%NSE
- 14 AprshareholdingShareholding · 31 Mar 2026+1.8%NSE
- 22 JanresultsResults · Q3 FY26 · standalone+2.6%NSE
- 19 JanshareholdingShareholding · 31 Dec 2025-1.8%NSE
Reaction to results · all yearsrose on day 0 in 10 of 22 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q2 FY27 | 29 Oct 2026 | +1.3% | +6.0% | — | 10.8× |
| Q1 FY27 | 30 Jul 2026 | +5.9% | +21.4% | +23.2% | 2.8× |
| Q4 FY26 | 14 May 2026 | -1.8% | -2.4% | -1.2% | 1.8× |
| Q3 FY26 | 22 Jan 2026 | +2.6% | +6.2% | +5.7% | 3.3× |
| Q2 FY26 | 6 Nov 2025 | +2.8% | +1.6% | -0.8% | 1.6× |
| Q1 FY26 | 1 Aug 2025 | -3.5% | -7.3% | -6.3% | 1.6× |
| Q4 FY25 | 15 May 2025 | -5.3% | -7.4% | -15.9% | 2.1× |
| Q3 FY25 | 23 Jan 2025 | -1.5% | +2.9% | -9.6% | 2.0× |
| Q2 FY25 | 24 Oct 2024 | -9.9% | +1.0% | +2.6% | 2.7× |
| Q1 FY25 | 25 Jul 2024 | -2.9% | +0.9% | +18.0% | 1.3× |
| Q4 FY24 | 25 Apr 2024 | +8.6% | +10.7% | +10.9% | 5.5× |
| Q3 FY24 | 23 Jan 2024 | +1.2% | +8.4% | +11.1% | 1.0× |
| Q2 FY24 | 20 Oct 2023 | -0.7% | +0.2% | +0.3% | 0.5× |
| Q1 FY24 | 21 Jul 2023 | +0.1% | +5.6% | +0.8% | 1.7× |
| Q4 FY23 | 28 Apr 2023 | +5.2% | +12.8% | +13.5% | 10.3× |
| Q3 FY23 | 27 Jan 2023 | -0.8% | -3.6% | -3.7% | 1.1× |
| Q2 FY23 | 22 Oct 2022 | +3.2% | +7.1% | +2.9% | 0.3× |
| Q1 FY23 | 5 Aug 2022 | -0.6% | -1.2% | -2.6% | 1.0× |
| Q4 FY22 | 21 Apr 2022 | -0.1% | -1.6% | -9.9% | 1.0× |
| Q3 FY22 | 8 Feb 2022 | -2.3% | -8.1% | -19.0% | 2.5× |
| Q2 FY22 | 11 Nov 2021 | +2.9% | -1.1% | -2.7% | 3.2× |
| Q1 FY22 | 13 Aug 2021 | -3.2% | -11.8% | -6.0% | — |
| Average | +0.0% | +1.8% | +0.5% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q2 FY27
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | +10.3% | +4.7% | +7.2% | — | — | — |
| Profit | +25.8% | +9.8% | +12.5% | — | — | — |
Key data
Delivery percentage
Over the last 20 sessions ALIVUS settled 51.7% of its traded quantity, which is above average for an NSE equity. That is in line with its own one-year average of 53.5%. The latest session ranks higher than 35% of the 1,308 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
Dividends, deals & holders
Performance returns
| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | -0.90% | -1.62% | +13.23% | +4.88% | +36.01% | +58.83% |
Valuation
Ownership
Quarterly results · standalone
| Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 672.9 | 689.1 | 640.4 | 682.0 |
| YoY chg | +4.8% | +6.1% | +6.4% | +16.0% |
| Net profit (₹ Cr) | 150.3 | 162.7 | 160.1 | 196.7 |
| YoY chg | +9.7% | +14.7% | +31.7% | +51.3% |
| Net margin | 22.3% | 23.6% | 25.0% | 28.8% |
| EPS | 12.22 | 13.22 | 13.01 | 15.98 |
Shareholding over time
By quarter
30 Sept 2026 · promoter 74.85% · public 25.15%- Promoter
- Public and others
- Promoter
- 74.85%
- Public
- 25.15%
- Promoter change
- -0.02 pp
- Filed
- 14 Oct 2026
- FII
- 5.93%
- DII
- 7.03%
- Promoter pledged
- 0.00%
Who the public is
- Mutual funds
- 5.29%
- Insurance
- 0.24%
- FPI
- 5.93%
- Retail ≤ ₹2L
- 9.00%
- HNI > ₹2L
- 1.11%
- NRI
- 0.64%
- Bodies corporate
- 1.17%
- Shareholders
- 1,22,777
-0.36 pp QoQ
-0.03 pp QoQ
+0.39 pp QoQ
-0.30 pp QoQ
+0.36 pp QoQ
-0.05 pp QoQ
-0.10 pp QoQ
-2.2% QoQ
Major holders
As of 30 Sept 2026| Holder | Type | Holding | Shares |
|---|---|---|---|
| Nirma Limited | Promoter · Corporate | 74.85% | 9.19Cr |
| Quant Mutual Fund - Quant Small Cap Fund | Mutual fund | 2.85% | 35.04L |
| Government Pension Fund Global | FPI | 2.33% | 28.65L |
| Massachusetts Institute of Technology | FPI | 1.23% | 15.04L |
| Old Bridge Focused Fund | Mutual fund | 1.07% | 13.20L |
Every promoter-group member, and each public holder above 1%, as filed.
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional, pledge and public-breakdown figures come from the filing's XBRL, which most filings before Sep-2021 lack, so they are absent there rather than zero. Changes are against the previous filing.
Dividends
| Financial year | Payments | Declared | Adjusted |
|---|---|---|---|
| FY2026-27 | 1 | ₹5.00 | ₹5.00 |
| FY2025-26 | 1 | ₹5.00 | ₹5.00 |
| FY2023-24 | 1 | ₹22.50 | ₹22.50 |
| FY2022-23 | 2 | ₹31.50 | ₹31.50 |
| FY2021-22 | 1 | ₹10.50 | ₹10.50 |
| Ex-date | Record date | Declared | Adjusted |
|---|---|---|---|
| 1 Sept 2026 | — | ₹5.00 | ₹5.00 |
| 1 Sept 2025 | — | ₹5.00 | ₹5.00 |
| 17 Oct 2023 | — | ₹22.50 | ₹22.50 |
| 24 Mar 2023 | — | ₹21.00 | ₹21.00 |
| 15 Sept 2022 | — | ₹10.50 | ₹10.50 |
| 22 Nov 2021 | — | ₹10.50 | ₹10.50 |
Rupees per share by ex-date, from NSE’s corporate actions; the record date is who was paid. Declared is the figure in the filing; adjusted restates it for splits and bonuses since, on the same basis as the price chart. Financial years run April to March.
52-week highs & lows
Each session the stock traded past its previous 52-week high or low, from NSE's daily report; the previous figure is the record it broke. Prices as published, not split-adjusted.
Book closures & record dates
NSE's corporate-action calendar: who held the stock on the record date, or through the book-closure window, was entitled to the dividend, bonus, split or rights named.
Insider trades
- Insiders net, 30d
- ₹0
- Insiders net, 90d
- ₹0
- Promoters net, 90d
- ₹0
- Insider buyers, 90d
- 0
- Last promoter buy
- 5.0 years ago
- Disclosures on record
- 8
| Broadcast | Person | Side | Shares | Value | Price | Holding before → after | Stake | Regulation |
|---|---|---|---|---|---|---|---|---|
| 17 Nov 2021 | GLENN SALDANHAPromoter | Buy | 7.5K | ₹48.3L | 643.19 | 295 → 7.8K | 0.00%0.00 pp | 7(2)told 17 Nov 2021 |
| 17 Nov 2021 | GLENN SALDANHAPromoter | Buy | 295 | ₹1.9L | 640.77 | — → 295 | 0.00% | 7(2)told 17 Nov 2021 |
SEBI insider-trading disclosures, equity only. Dated by the day NSE broadcast them; the trade itself is often weeks earlier. The figures count promoters, directors and KMPs buying or selling on the exchange — not ESOPs, gifts, transfers within the promoter group or pledges. Stake is the holding after, as filed; the change beneath it scales that by the share counts before and after. Regulation is the PIT clause cited, and “told” the day the insider informed the company.
How the insider figures are countedPromoters buying in the open market, market-wideEvery stock on this session
Bulk & block deals · 6 Nov 2026
CSV| Date | Deal | Client | Quantity | Price | Value |
|---|---|---|---|---|---|
| 6 Nov 2026 | Sell · block, also bulk | NIRMA LIMITED | 28.46L | 1,370.00 | ₹389.9Cr |
| 6 Nov 2026 | Buy · block, also bulk | PARAM CAPITAL | 7.30L | 1,370.00 | ₹100.0Cr |
| 6 Nov 2026 | Buy · block | BANDHAN MUTUAL FUND | 6.00L | 1,370.00 | ₹82.2Cr |
| 6 Nov 2026 | Buy · block | SETU SECURITIES PRIVATE LIMITED | 4.10L | 1,370.00 | ₹56.2Cr |
| 6 Nov 2026 | Buy · block | SUBHKAM VENTURES I PVT LTD | 2.50L | 1,370.00 | ₹34.3Cr |
| 6 Nov 2026 | Buy · block | SANSHI FUND - I | 2.00L | 1,370.00 | ₹27.4Cr |
| 6 Nov 2026 | Buy · block | BANDHAN MUTUAL FUND | 2.00L | 1,370.00 | ₹27.4Cr |
| 6 Nov 2026 | Buy · block | NORGES BANK ON ACCOUNT OF THE GOVERNMENT PENSION FUND GLOBAL | 1.83L | 1,370.00 | ₹25.1Cr |
| 6 Nov 2026 | Buy · block | HELIOS MUTUAL FUND | 1.16L | 1,370.00 | ₹15.9Cr |
| 6 Nov 2026 | Buy · block | HELIOS MUTUAL FUND | 1.01L | 1,370.00 | ₹13.9Cr |
| 6 Nov 2026 | Buy · block | BANDHAN MUTUAL FUND | 38.1K | 1,370.00 | ₹5.2Cr |
| 6 Nov 2026 | Buy · block | BANDHAN MUTUAL FUND | 17.8K | 1,370.00 | ₹2.4Cr |
A bulk deal is a client trading over 0.5% of the company’s shares in a day; a block deal is one large trade in the separate block window. Quantities and prices are as NSE published them, not split-adjusted.
Short selling, lending & margin
Shares sold short on the day, as brokers reported them to NSE at the close. As reported, not split-adjusted.
Exchange surveillance
No surveillance measure applies to ALIVUS.
Price band: 20% · not in the F&O ban.
From NSE’s daily surveillance, price-band and position-limit files. A stock enters the F&O ban when open interest passes 95% of its market-wide position limit and leaves it below 80%; until then no new positions can be opened. CSV: measures · band changes.
Every stock on this session →Financials · quarterly statement
| Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Q2 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 572.8 | 536.6 | 588.6 | 506.9 | 641.8 | 649.5 | 601.8 | 588.0 | 672.9 | 689.1 | 640.4 | 682.0 | |
| Other income | 1.7 | 3.1 | 5.5 | 8.5 | 10.5 | 10.1 | 9.0 | 14.7 | 13.9 | 22.8 | 22.4 | 19.9 | |
| Total income | 574.5 | 539.7 | 594.1 | 515.4 | 652.3 | 659.6 | 610.8 | 602.7 | 686.8 | 711.9 | 662.8 | 701.9 | |
| Total expenses | 413.8 | 410.0 | 443.9 | 388.0 | 467.2 | 468.3 | 447.9 | 428.6 | 462.8 | 496.1 | 450.6 | 439.9 | |
| └ Finance costs | 0.4 | 0.4 | 0.4 | 0.3 | 0.5 | 1.3 | 1.3 | 1.3 | 1.5 | 1.3 | 1.3 | 1.3 | |
| └ Depreciation | 13.2 | 14.5 | 14.4 | 15.1 | 15.2 | 16.0 | 17.1 | 18.4 | 19.7 | 20.2 | 20.6 | 21.8 | |
| Profit before tax | 160.7 | 129.7 | 150.2 | 127.5 | 185.1 | 191.3 | 163.0 | 174.1 | 198.4 | 215.8 | 212.2 | 262.0 | |
| Tax expense | 41.9 | 31.7 | 38.8 | 32.1 | 48.2 | 49.4 | 41.4 | 44.1 | 48.1 | 53.1 | 52.1 | 65.2 | |
| Net profit | 118.8 | 97.9 | 111.5 | 95.3 | 137.0 | 141.9 | 121.5 | 130.0 | 150.3 | 162.7 | 160.1 | 196.7 | |
| EPS | 9.69 | 7.99 | 9.10 | 7.78 | 11.18 | 11.57 | 9.91 | 10.60 | 12.25 | 13.23 | 13.04 | 16.02 | |
| Net margin | 20.73% | 18.25% | 18.94% | 18.80% | 21.34% | 21.84% | 20.19% | 22.11% | 22.33% | 23.60% | 25.00% | 28.85% | |
| PBT margin | 28.05% | 24.17% | 25.52% | 25.15% | 28.85% | 29.45% | 27.08% | 29.62% | 29.48% | 31.32% | 33.14% | 38.41% | |
| Tax rate | 26.09% | 24.48% | 25.80% | 25.22% | 26.03% | 25.84% | 25.43% | 25.33% | 24.26% | 24.62% | 24.57% | 24.90% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. The balance sheet and cash flow arrive only with the half-year and annual filings, and are in their own section below. Latest filed 29 Oct 2026.
Balance sheet & cash flow · half-yearly
Balance sheet
| FY23 | H1 FY24 | FY24 | H1 FY25 | FY25 | H1 FY26 | FY26 | H1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2,702.1 | 2,953.0 | 2,850.4 | 3,084.9 | 3,411.5 | 3,638.3 | 3,982.9 | 4,341.9 | |
| Current assets | 1,850.3 | 2,076.7 | 1,916.0 | 2,096.1 | 2,335.2 | 2,475.9 | 2,649.4 | 2,864.8 | |
| └ Cash & equivalents | 283.8 | 442.9 | 301.4 | 446.1 | 71.1 | 18.9 | 2.0 | 25.4 | |
| └ Other bank balances | 25.6 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | |
| └ Current investments | 0.0 | 0.0 | 0.0 | 0.0 | 477.6 | 633.6 | 780.4 | 986.2 | |
| └ Trade receivables | 806.8 | 807.5 | 765.4 | 775.1 | 969.7 | 1,002.8 | 1,073.0 | 988.2 | |
| └ Inventories | 604.2 | 669.5 | 666.6 | 689.2 | 673.9 | 722.5 | 691.9 | 782.8 | |
| Total equity | 2,138.2 | 2,391.7 | 2,332.3 | 2,538.5 | 2,817.4 | 3,015.4 | 3,332.1 | 3,631.3 | |
| └ Attributable to owners | 2,138.2 | 2,391.7 | 2,332.3 | 2,538.5 | 2,817.4 | 3,015.4 | 3,332.1 | 3,631.3 | |
| └ Share capital | 24.5 | 24.5 | 24.5 | 24.5 | 24.5 | 24.5 | 24.5 | 24.6 | |
| Borrowings | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| └ Current | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| └ Non-current | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Trade payables | 396.6 | 385.2 | 368.7 | 398.2 | 390.5 | 409.9 | 372.4 | 427.3 | |
| Current liabilities | 504.4 | 499.0 | 438.8 | 463.7 | 470.2 | 489.3 | 508.0 | 563.7 | |
| Total liabilities | 563.9 | 561.2 | 518.1 | 546.4 | 594.1 | 623.0 | 650.8 | 710.7 | |
| Net debt | (309.4) | (443.1) | (301.6) | (446.3) | (548.9) | (652.8) | (782.5) | (1,011.7) | |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Current ratio | 3.67 | 4.16 | 4.37 | 4.52 | 4.97 | 5.06 | 5.21 | 5.08 |
Cash flow, year to date
| FY23 | H1 FY24 | FY24 | H1 FY25 | FY25 | H1 FY26 | FY26 | H1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 313.4 | 216.2 | 413.5 | 219.6 | 391.5 | 260.7 | 565.4 | 459.7 | |
| └ Capex | (170.2) | (62.7) | (129.0) | (85.6) | (166.2) | (113.0) | (307.1) | (189.5) | |
| Free cash flow | 143.2 | 153.5 | 284.5 | 133.9 | 225.3 | 147.7 | 258.4 | 270.2 | |
| Investing cash flow | (154.1) | (55.2) | (116.5) | (73.1) | (615.6) | (252.4) | (570.2) | (370.9) | |
| Financing cash flow | (387.6) | (1.9) | (279.4) | (1.8) | (6.2) | (60.5) | (64.3) | (65.4) | |
| └ Dividends paid | (385.9) | 0.0 | (275.7) | 0.0 | 0.0 | (61.3) | (61.3) | (61.4) | |
| └ Buybacks | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Net change in cash | (228.3) | 159.1 | 17.6 | 144.7 | (230.4) | (52.1) | (69.1) | 23.5 |
From the half-year and annual results filings: the balance sheet from September 2022, the cash flow from September 2020. Those are when NSE’s XBRL began to carry each statement; earlier filings have it only in the attached PDF. Cash flow columns are year to date, so an H1 column covers April to September and an FY column the full year. Outflows are in parentheses. Net debt is borrowings less cash, bank balances and current investments; for banks, NBFCs and insurers it, debt to equity and the current ratio are left blank because their statements are not built that way.
Announcements & board meetings
As the company filed them with NSE, newest first. Board meetings are dated by the meeting, which is usually a week or more after the intimation.
Every stock on this session →ALIVUS at a glance
- ALIVUS closed at ₹1,436.9 on 20 Nov 2026, -0.90% on the day, +58.8% over one year, 8.7% below its 52-week high of ₹1,574.
- Delivery was 51.2% of traded quantity on 20 Nov 2026, the 35th percentile of its own 1,308 sessions with a reading (20-session average 51.7%, 1-year average 53.5%).
- Market capitalisation is ₹17,669 crore at a trailing P/E of 26.4 (trailing EPS ₹54.47).
- Q2 FY27 results (standalone, filed 29 Oct 2026): revenue ₹682 crore (+16.0% year on year), net profit ₹197 crore (+51.3%); the price moved +1.3% on the first session after.
- Promoters held 74.85% at 30 Sept 2026, down 0.02 percentage points on the previous filing.
- Q3 FY27 results are expected between 22 Jan 2027 and 8 Feb 2027, going by past filing dates — an estimate, not an announcement.
About
Sector history
- to 16 Aug 2026Index industry · Healthcare
- from 16 Aug 2026Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
NSE’s own classification, by the snapshot it changed on.
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 20 Nov 2026.
More in Pharmaceuticals & Biotechnology
- DIDIVISLABDivi's Laboratories Limited11,180.50+0.02%
- LALAURUSLABSLaurus Labs Limited2,294.60-0.49%
- SUSUNPHARMASun Pharmaceutical Industries Limited1,884.90-0.79%
- ACACUTAASAcutaas Chemicals Limited3,833.50-3.61%
- SASAILIFESai Life Sciences Limited1,800.70+0.69%
- PPPPLPHARMAPiramal Pharma Limited239.30-0.15%
- DRDRREDDYDr. Reddy's Laboratories Limited1,390.20-0.76%
- GLGLENMARKGlenmark Pharmaceuticals Limited2,648.00+1.51%
- AUAUROPHARMAAurobindo Pharma Limited1,799.00-0.37%
- CICIPLACipla Limited1,415.00-0.25%
- ZYZYDUSLIFEZydus Lifesciences Limited1,200.00-0.24%
- MAMANKINDMankind Pharma Limited2,665.00+1.37%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE